Exact Sciences Advances Innovative Cancer Technologies and Approaches Through Visionary Collaborations
Agreements with Broad Institute of MIT and Harvard provide exclusive license to next-generation technology for ultra-sensitive detection of molecular residual disease and ongoing research
Collaboration with Baylor Scott & White creates real-world experience and evidence supporting Exact Sciences' multi-cancer early detection approach
"These collaborations mark a significant milestone in Exact Sciences' pursuit to eradicate cancer," said Jorge Garces, Chief Science Officer at Exact Sciences. "Our combined efforts will unlock new insights into the complexities of cancer. We hope to enable preventive measures and treatments that address the unique needs of each patient to maximize their chances of achieving positive outcomes."
Agreements with Broad Institute of MIT and Harvard provide exclusive license to next-generation technology for ultra-sensitive detection of molecular residual disease and ongoing research
Exact Sciences and Broad Institute have entered into a 5-year sponsored research agreement and an exclusive license agreement to utilize Minor Allele Enriched Sequencing Through Recognition Oligonucleotides (MAESTRO) as its molecular residual disease diagnostic testing platform. MAESTRO is a next-generation circulating tumor DNA technology that can detect thousands of patient-specific mutations using minimal sequencing and advanced bioinformatics, creating a scalable test platform for enhanced detection of molecular residual disease. The Broad Institute is globally recognized for leading innovations in the field of genomics and next-generation sequencing methodology. MAESTRO was developed at the Broad Institute's Gerstner Center for Cancer Diagnostics which is focused on breakthrough innovations for significant unmet needs in cancer diagnostics.
Collaboration with Baylor Scott & White creates real-world experience and evidence supporting Exact Sciences' multi-cancer early detection (MCED) approach
Exact Sciences and Baylor Scott & White (BSW) have entered an agreement to establish the Texas Multicancer Early Detection Registry program, including implementation of Exact Sciences' MCED test within a subset of BSW primary care clinics. As part of the program, Exact Sciences will generate real-world evidence related to MCED testing in a clinical setting and provide comprehensive support to patients, ordering providers, and clinical staff. The program aims to provide about 50,000 testing opportunities over three years, helping optimize the clinical workflows of MCED testing. The collaboration will also generate data to support discussions with regulatory agencies, payers, and guideline bodies.
About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.
Forward-Looking Statement
This news release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially from those anticipated. There can be no assurance that we will (i) realize the anticipated benefit from any of the above-described agreements, or (ii) successfully develop any products or services utilizing MAESTRO or any MCED test. Therefore, you should not place undue reliance on forward-looking statements. Risks and uncertainties that may affect our forward-looking statements are described in the Risk Factors sections of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Exact Sciences Contacts
Media: Morry Smulevitz, +1 608-345-8010, msmulevitz@exactsciences.com
Investors: Megan Jones, +1 608-535-8815, meganjones@exactsciences.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/exact-sciences-advances-innovative-cancer-technologies-and-approaches-through-visionary-collaborations-301856636.html
SOURCE Exact Sciences Corporation
